ENRICO CALIMAN1,2, SARA FANCELLI1,2, FEDERICO SCOLARI3, ADRIANO PASQUI4, CLARA MANNESCHI4, DANIELE LAVACCHI1, FRANCESCA MAZZONI4, FRANCESCA GENSINI5, VALERIA PASINI6, CAMILLA EVA COMIN2,7, LUCA VOLTOLINI2,8, SERENA PILLOZZI1,2,*, LORENZO ANTONUZZO1,2,4
Oncology Research, Vol.33, No.1, pp. 45-55, 2025, DOI:10.32604/or.2024.050161
- 20 December 2024
Abstract Background: Platinum chemotherapy (CT) remains the backbone of systemic therapy for patients with small-cell lung cancer (SCLC). The nucleotide excision repair (NER) pathway plays a central role in the repair of the DNA damage exerted by platinum agents. Alteration in this repair mechanism may affect patients’ survival. Materials and Methods: We conducted a retrospective analysis of data from 38 patients with extensive disease (ED)-SCLC who underwent platinum-CT at the Clinical Oncology Unit, Careggi University Hospital, Florence (Italy), from 2015 to 2020. mRNA expression analysis and single nucleotide polymorphism (SNP) characterization of three NER pathway genes—namely ERCC1, ERCC2,… More >
Login
Register
